Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONDI
2024-513595-17-00Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN), diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM) comparing ODM-111 with Placebo (2 arms). Primary endpoint: Change in weekly average of daily pain intensity from baseline to week 6. Started Oct 2024; status: completed.
02
Drugs
JMKX000623
03
Conditions
diabetic polyneuropathy (DPN)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-513595-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513595-17-00.